Baptist Health Brain & Spine Care is enrolling patients with confirmed multiple sclerosis who are starting BRUMVI to track outcomes, safety, and patient experience over time in a real-world setting.
Why this study matters to clinicians
Randomized trials establish efficacy and safety under controlled conditions—but clinicians often want to know how therapies perform across everyday practice. This observational registry collects real-world information over time on patients receiving FDA-approved BRUMVI (TG Therapeutics) to better understand outcomes, safety, and patient experience in relapsing multiple sclerosis.
Study snapshot
- Type: Observational registry (non-interventional)
- Therapy: FDA-approved infusion medication BRUMVI
- Participant activities: Sharing health information plus questionnaires and brief assessments while continuing usual care
- Timeline: Enrollment plus BRUMVI infusions 1 to 10, totaling 192 weeks of therapy
Who to consider referring (quick eligibility scan)
Inclusion highlights (not exhaustive):
- Confirmed multiple sclerosis diagnosis
- No BRUMVI infusions prior to study start
- Prescribed BRUMVI and not yet received the first infusion on Day 1 (150 mg) may be eligible
- Additional criteria may apply
Key exclusion highlights (not exhaustive):
- Recent vaccines: live/live-attenuated within 4 weeks or non-live within 2 weeks prior to first BRUMVI administration
- Active infection (e.g., active hepatitis B virus) at time of first BRUMVI administration
- Concurrent participation in interventional MS trials or planned concurrent MS disease-modifying therapy during the study period
What participation looks like (in plain terms)
Because this is a registry, patients generally continue their usual clinical care. Participants may be asked to complete two questionnaires and brief assessments aligned with enrollment and infusion visits.
How to refer or learn more
This registry can be a good fit for patients with relapsing multiple sclerosis who are about to start BRUMVI and are open to contributing real-world data while receiving standard care.
To learn more or refer a patient, please email NeuroResearch@BaptistHealth.net or call 786-596-1845.
